Intradermal vaccination of HPV-16 E6 synthetic peptides conjugated to an optimized Toll-like receptor 2 ligand shows safety and potent T cell immunogenicity in patients with HPV-16 positive (pre-)malignant lesions.
Frank M SpeetjensMarij J P WeltersMarije SlingerlandMariette I E van PoelgeestPeggy J de Vos van SteenwijkInge RoozenSanne BoekestijnNikki M LoofGijs G ZomA Rob P M ValentijnWillem-Jan KrebberNico J MeeuwenoordCatharina A H JanssenCornelis J M MeliefGijs A van der MarelDmitri V FilippovSjoerd H van der BurgHans GelderblomFerry OssendorpPublished in: Journal for immunotherapy of cancer (2022)
NCT02821494 and 2014-000658-12.